Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in CD20-directed Cytolytic Antibody [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
RITUXIMAB 178,614 28,910 16.2% 54,631 13,612 54.6 yrs 64.3%
OCRELIZUMAB 56,186 1,406 2.5% 10,364 629 47.2 yrs 72.5%
OFATUMUMAB 29,913 695 2.3% 3,616 384 47.5 yrs 74.9%
OBINUTUZUMAB 14,189 1,919 13.5% 5,419 678 63.8 yrs 41.7%
UBLITUXIMAB 1,582 27 1.7% 213 7 49.7 yrs 73.4%

Head-to-Head Comparisons

RITUXIMAB vs OCRELIZUMAB RITUXIMAB vs OFATUMUMAB RITUXIMAB vs OBINUTUZUMAB RITUXIMAB vs UBLITUXIMAB OCRELIZUMAB vs OFATUMUMAB OCRELIZUMAB vs OBINUTUZUMAB OCRELIZUMAB vs UBLITUXIMAB OFATUMUMAB vs OBINUTUZUMAB OFATUMUMAB vs UBLITUXIMAB OBINUTUZUMAB vs UBLITUXIMAB
← Back to CD20-directed Cytolytic Antibody [EPC] Class side effects →